United Therapeutics Corp. (UTHR) announced that it received a complete response letter from the United States Food and Drug Administration or FDA declining to approve its new drug application or NDA for treprostinil diethanolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension or PAH.
The FDA letter questioned the clinical importance of the 6 Minute Walk Distance or 6MWD effect size shown in the FREEDOM-M study, the inability to demonstrate an improvement in time to clinical worsening in all three Phase III studies of oral treprostinil, and the inability to demonstrate a statistically significant effect on 6MWD in the two FREEDOM-C studies as reasons for being unable to approve the NDA in its current form.
The FDA noted that it was unsure whether an additional clinical study could alter these impressions, but if United Therapeutics did undertake an additional study it should consider, among other things, a fixed dose design and more frequent dosing.
"We will continue using our best efforts to gain approval of oral treprostinil, and we will focus on doing so within the next four years. We will convene with our experts over the next several weeks to decide which of several paths forward to pursue," said Martine Rothblatt, Chairman and Chief Executive Officer.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.